Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.

You may also be interested in...



Eisai, J&J’s Aciphex Cleared For Adolescent GERD

Other PPI’s already bear the broader label.

Eisai, J&J’s Aciphex Cleared For Adolescent GERD

Other PPI’s already bear the broader label.

J&J Combines Ortho Biotech, Centocor

At least 400 jobs lost to fallout from anemia-drug troubles.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel